Preparing for PRRT： What Patients Need to Know • Dr. Muzahir • 2026 Patient Conference in Atlanta

In this video, Dr. Muzahir explains the role of nuclear medicine in peptide receptor radionuclide therapy, or PRRT, for patients with neuroendocrine tumors. The presentation discusses how PRRT uses a targeted treatment called lutetium dotatate to deliver radiation directly to neuroendocrine tumor cells that express somatostatin receptors. Dr. Muzahir also explains the concept of theranostics, which combines diagnosis and therapy to help guide personalized cancer care. Topics include: • What PRRT is and how it works • The role of nuclear medicine in neuroendocrine tumor care • How lutetium dotatate targets somatostatin receptors • The meaning of theranostics • The importance of a multidisciplinary care team • What patients may expect during treatment • Possible side effects and long-term risks • Radiation safety for patients, caregivers, and families This talk is helpful for patients, caregivers, and anyone interested in learning more about PRRT and nuclear medicine treatment options for neuroendocrine tumors. ___________________________________________________________ ABOUT Neuroendocrine Cancer Patient Education Conference Atlanta, GA May 16, 2026 The Neuroendocrine Cancer Foundation (NCF) hosted a free, in-person educational conference at the Emory Winship Cancer Institute designed specifically for people living with neuroendocrine cancer and their caregivers. This one-day program brought together leading experts from Emory University, the University of Alabama at...